ReviewPharmacological reports : PR2026
Upadacitinib as rescue therapy for acute severe ulcerative colitis and severe Crohn's disease - current knowledge and future directions.
Review in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute severe ulcerative colitis (ASUC) and acute severe Crohn's disease (CD) flare are potentially life-threatening conditions, for which treatment remains a clinical challenge. Currently available therapeutic options present limited efficacy, with a high rate of colectomy as the final-line treatment method. Therefore, new alternatives of rescue therapy in inflammatory bowel diseases (IBD) are constantly sought. Upadacitinib (UPA), a selective Janus kinase-1 (JAK1) inhibitor, has been approved for the treatment of moderate-to-severe ulcerative colitis (UC) and CD. Interestingly, the most recent data show an increasing off-label use of this medication in the management of acute severe colitis. We present a comprehensive review focusing on rescue therapy with UPA in IBD, both UC and CD. The article examines the outcomes of recent studies evaluating the effectiveness, safety, and tolerability of UPA treatment in adult patients with ASUC and severe CD flare, a new treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.